You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Local advanced

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Local Advanced NSCLC Trial (Toripalimab, Radical thoracic radiotherapy)

Not yet recruiting
  • Local Advanced Non-small Cell Lung Cancer
  • (no location specified)
Jun 2, 2023

Rectal Cancer Trial in Chongqing (CIETAI-R)

Recruiting
  • Rectal Cancer
  • CIETAI-R
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
Jul 21, 2023

Advanced Urothelial Carcinoma Trial in Beijing (9MW2821, Toripalimab)

Not yet recruiting
  • Advanced Urothelial Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 9, 2023

Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

Recruiting
  • Locally Advanced Rectal Cancer
  • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
  • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 25, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Beijing, Beijing, China
    Beijing Tongren Hospital
Oct 26, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

NSCLC Trial in Guangzhou (chest radiation, concurrent chemo, Methylprednisolone)

Terminated
  • Non-small Cell Lung Cancer
  • chest radiation
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Nov 25, 2022

NSCLC Trial in Guangzhou (split-course radiotherapy, concurrent chemo)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • split-course radiotherapy
  • concurrent chemotherapy
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Local Advanced Esophageal Carcinoma

Recruiting
  • Esophageal Squamous Cell Carcinoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai cancer center
    Jun 16, 2022

    Metastatic or Local Advanced Breast Cancer of Patients Trial in Beijing, Changchun (HRS-8080 tablets?SHR 6390

    Enrolling by invitation
    • Metastatic or Local Advanced Breast Cancer of Patients
    • HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
    • Beijing, Beijing, China
    • +1 more
    Apr 2, 2022

    Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

    Recruiting
    • Solid Tumor, Adult
    • +4 more
    • KRAS-EphA-2-CAR-DC
    • +3 more
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinsese PLA Gereral Hospital
    Nov 29, 2022

    Breast Cancer Trial (HRS-1358)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Nov 17, 2022

    Local Advanced High Risk Nasopharyngeal Carcinoma Trial in Guangzhou (IMRT combine with cisplatin concurrent chemo, IMRT combine

    Active, not recruiting
    • Local Advanced High Risk Nasopharyngeal Carcinoma
    • IMRT combine with cisplatin concurrent chemotherapy
    • IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Mar 13, 2022

    Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • +3 more
    • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
    • Hefei, China
      Anhui provincial hospital
    Apr 16, 2023

    Local Advanced High Risk Nasopharyngeal Carcinoma Trial in Guangzhou (IMRT combine with cisplatin concurrent chemo, IMRT combine

    Recruiting
    • Local Advanced High Risk Nasopharyngeal Carcinoma
    • IMRT combine with cisplatin concurrent chemotherapy
    • IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Apr 9, 2022

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

    Recruiting
    • Colorectal Cancer
    • +3 more
    • Neoadjuvant therapy with PD-L1 inhibitor
    • Guangzhou, Guangdong, China
      the Third Affiliated Hospital of Sun Yat-Sen University
    May 10, 2022

    HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

    Not yet recruiting
    • HER2 Positive Advanced Solid Tumors
    • HypoSti.CAR-HER2 T cells
    • +2 more
    • (no location specified)
    Jan 12, 2023

    Rectal Cancer Trial in Shanghai (FOLFOXIRI, CapeOX)

    Recruiting
    • Rectal Cancer
    • Shanghai, Shanghai, China
      Department of Colorectal Surgery Fudan University Shanghai Caner
    Feb 16, 2022

    Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

    Not yet recruiting
    • Gastric Cancer
    • Beijing, China
      Beijing Cancer Hospital
    Aug 7, 2023

    Urinary Bladder Cancer Trial in Guangzhou (Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin)

    Recruiting
    • Urinary Bladder Cancer
    • Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
    • Guangzhou, Guangdong, China
      Zhujiang Hospital
    Jan 6, 2023

    Advanced Solid Tumors Trial in Worldwide (BMS-986449, Nivolumab)

    Not yet recruiting
    • Advanced Solid Tumors
    • Los Angeles, California
    • +19 more
    May 25, 2023

    Colorectal Cancer, Adjuvant Chemo Trial in Guangzhou (wait and watch, adjuvant chemo)

    Recruiting
    • Colorectal Cancer
    • Adjuvant Chemotherapy
    • wait and watch
    • adjuvant chemotherapy
    • Guangzhou, Guangdong, China
      Sixth Affiliated Hospital of Sun Yat-sen University
    Jan 25, 2022

    Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

    Completed
    • Gastric Cancer
    • HER2 Overexpressing Gastric Carcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jan 12, 2022

    Rectal Cancer Trial in Fuzhou (radiation, drug, procedure)

    Not yet recruiting
    • Rectal Cancer
    • split-course hypofraction radiotherapy
    • +3 more
    • Fuzhou, Fujian, China
      Pan Chi
    Jul 23, 2023